SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Publicacións nas que colabora con JAVIER PUENTE VÁZQUEZ (10)
2018
-
Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)
Breast Cancer Research and Treatment
-
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634
2011
-
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136
-
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132
2010
-
Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma
Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1
-
Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600
2009
-
Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis
Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187
2006
-
Cáncer de pulmón no microcítico: quimioterapia y otros tratamientos sistémicos
Psicooncología: investigación y clínica biopsicosocial en oncología, Vol. 3, Núm. 2, pp. 229-248
-
Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma
Clinical and Translational Oncology, Vol. 8, Núm. 9, pp. 676-680
2005
-
Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
Clinical Breast Cancer, Vol. 6, Núm. 4, pp. 325-329